Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.73 |
| ▸ | STK4 | Q13043 | 3/20 | 0.73 |
| ▸ | STK25 | O00506 | 2/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 2/20 | 0.73 |
| ▸ | STK17B | O94768 | 2/20 | 0.73 |
| ▸ | STK10 | O94804 | 2/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 2/20 | 0.73 |
| ▸ | FES | P07332 | 2/20 | 0.73 |
| ▸ | CSF1R | P07333 | 2/20 | 0.73 |
| ▸ | YES1 | P07947 | 2/20 | 0.73 |
| ▸ | LYN | P07948 | 2/20 | 0.73 |
| ▸ | MET | P08581 | 2/20 | 0.73 |
| ▸ | HCK | P08631 | 2/20 | 0.73 |
| ▸ | FGR | P09769 | 2/20 | 0.73 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129849 | 0.92 | EGFR (0.71) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL2130178 | 0.89 | EGFR (0.93) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL2130569 | 0.87 | ERBB2 (0.94) | EGFRERBB2STK4STK25CHEK1 | |
| SCHEMBL2133444 | 0.86 | EGFR (0.65) | EGFRERBB2KDRJAK3ERBB4 | |
| Neratinib SCHEMBL571763 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL29801657 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL29394766 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL15163655 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL15163654 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 | |
| Neratinib SCHEMBL571762 | 0.85 | ERBB2 (1.00) | EGFRERBB2STK4STK25CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748453-B2 | Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof | MEDOLUTION LIMITED (HK) | 2014-06-10 | — | — | US | claimed |
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | claimed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | claimed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | claimed |
| US-8748453-B2 | Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof | MEDOLUTION LIMITED (HK) | 2014-06-10 | — | — | US | disclosed |
| EP-2445885-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | Medolution Limited (CN) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MEDOLUTION LIMITED (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2010151710-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF | MEDOLUTION LIMITED (CN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101116-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF | MAP4K2, MAP3K7, MAP3K1 | EGFR 1263/4885ERBB2 464/4885STK4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.